



COMPANY OVERVIEW

Ekso Bionics® is a pioneer in the field of robotics. For over a decade we have been committed to developing the latest technology and engineering to commercialize wearable exoskeletons and robotic-assist devices in a variety of applications such as medical and industrial markets. Exoskeletons resolve unique customer challenges in rehabilitation allowing people to rethink their current physical limitations. Light-weight assist devices for industrial workers will help achieve mobility, strength, or endurance not otherwise possible. We remain committed to forming strategic partnerships for cutting-edge innovation. Ekso Bionics is headquartered in Northern California and listed under the symbol (NASDAQ: EKSO).

Learn more about Ekso Bionics [here](#)

RECENT NEWS

Ekso Bionics to Present at the Cantor Fitzgerald Global Healthcare Conference on October 3, 2018

Sep 26 2018, 8:00 AM EDT

STOCK OVERVIEW

Symbol	EKSO
Exchange	Nasdaq
Market Cap	123.49m
Last Price	\$2.03
52-Week Range	\$1.02 - \$4.77

INVESTOR RELATIONS

David Carey
T: 212-867-1768
investors@eksobionics.com

MANAGEMENT TEAM

Jack Peurach

President, Chief Executive Officer and Director

Jack Glenn

Chief Financial Officer

Russ DeLonzor

Chief Operating Officer

Christian Babini

Vice President of Sales, Americas

Matthias Stief

Managing Director, Ekso Bionics Europe GmbH

Chwee Foon Lim

President, APAC

Darrell Musick

Vice President, Clinical

Bianca Clinch Momand

Vice President, Sales North America

EKSO BIONICS HOLDINGS, INC.

1414 Harbour Way South
Suite 1201
Richmond, CA 94804
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.